Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial.

Publication date: Dec 01, 2026

We conducted a phase 2, randomized, active-controlled, observer-blind study (NCT05960097) among healthy adults ≥18 y of age who completed a primary COVID-19 mRNA vaccination series, with or without a booster, ≥3 months earlier. Participants were randomized (1:1:1:1:1) to either receive an investigational bivalent mRNA COVID-19 vaccine encoding ancestral D614G and Omicron BA. 4-5 spike proteins (CV0701 mRNA vaccine) at one of three dose levels, an investigational monovalent mRNA COVID-19 vaccine encoding the Omicron BA. 4-5 spike protein (CV0601 mRNA vaccine), or a licensed Original Wuhan/Omicron BA. 4-5 bivalent mRNA COVID-19 vaccine. The primary objectives were to evaluate reactogenicity, safety and immunogenicity post-vaccination. Secondary and tertiary objectives were to further evaluate humoral and cell-mediated immunity post-vaccination. In total, 425 participants were vaccinated and 381 were included in the Day 29 per-protocol immunogenicity analysis. Most solicited events were mild to moderate. No vaccine-related serious adverse events or myocarditis/pericarditis cases were reported. For the CV0701 mRNA vaccine, a dose-dependent increase in Day 29 neutralizing titers against ancestral D614G and Omicron BA. 4-5 was observed. Neutralizing titers against ancestral D614G and Omicron BA. 4-5 declined by Days 91 and 181, but remained above baseline. Similar immune responses were observed for the CV0601 mRNA vaccine. At Day 8, CD4+ T cells (Th1 profile) increased in all study groups and CD8+ T cells increased in all study groups, except the lowest CV0701 dose group. The CV0701 and CV0601 mRNA vaccines elicited robust humoral and cellular immunity with an acceptable safety profile, comparable to a licensed, bivalent mRNA vaccine. Clinical Trial Registration EU CT number: 2023-504596-25-00 ClinicalTrials. gov: NCT05960097.

Open Access PDF

Concepts Keywords
 Omicron BA.4-5
 SARS-CoV-2
 T-cell response
Adolescent
Adult
Ancestral D614G
Antibodies, Neutralizing
Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Humans
Immunity, Cellular
Immunity, Humoral
immunogenicity
Immunogenicity, Vaccine
licensed comparator
Male
Middle Aged
mRNA COVID-19 vaccine
mRNA Vaccines
mRNA Vaccines
reactogenicity
safety
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccination
Vaccines, Synthetic
Vaccines, Synthetic
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease MESH included
disease MESH myocarditis
disease MESH pericarditis

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *